- Home
- BTAI vs DSS Comparison
BTAI vs DSS Comparison
Compare BTAI & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- DSS
- Stock Information
- Founded
- BTAI 2017
- DSS 1984
- Country
- BTAI United States
- DSS United States
- Employees
- BTAI N/A
- DSS N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- DSS Containers/Packaging
- Sector
- BTAI Health Care
- DSS Consumer Discretionary
- Exchange
- BTAI Nasdaq
- DSS Nasdaq
- Market Cap
- BTAI 7.2M
- DSS 7.3M
- IPO Year
- BTAI 2018
- DSS N/A
- Fundamental
- Price
- BTAI $1.88
- DSS $0.87
- Analyst Decision
- BTAI Buy
- DSS
- Analyst Count
- BTAI 5
- DSS 0
- Target Price
- BTAI $42.60
- DSS N/A
- AVG Volume (30 Days)
- BTAI 1.2M
- DSS 82.9K
- Earning Date
- BTAI 03-27-2025
- DSS 03-31-2025
- Dividend Yield
- BTAI N/A
- DSS N/A
- EPS Growth
- BTAI N/A
- DSS N/A
- EPS
- BTAI N/A
- DSS N/A
- Revenue
- BTAI $2,266,000.00
- DSS $19,097,000.00
- Revenue This Year
- BTAI $105.36
- DSS N/A
- Revenue Next Year
- BTAI $46.93
- DSS N/A
- P/E Ratio
- BTAI N/A
- DSS N/A
- Revenue Growth
- BTAI 64.20
- DSS N/A
- 52 Week Low
- BTAI $1.72
- DSS $0.77
- 52 Week High
- BTAI $49.58
- DSS $2.30
- Technical
- Relative Strength Index (RSI)
- BTAI 39.27
- DSS 43.96
- Support Level
- BTAI $1.76
- DSS $0.78
- Resistance Level
- BTAI $2.37
- DSS $1.03
- Average True Range (ATR)
- BTAI 0.28
- DSS 0.10
- MACD
- BTAI 0.03
- DSS -0.00
- Stochastic Oscillator
- BTAI 16.95
- DSS 25.97
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.